Chimeric Therapeutics Limited

ASX (AUD): Chimeric Therapeutics Limited (CHM)

Last Price

0.007

Today's Change

+0.001 (16.66%)

Day's Change

0.006 - 0.007

Trading Volume

4,515,921

Profile
CHM

Exchange:  Australian Securities Exchange Australian Securities Exchange

Currency:  AUD AUD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD

Full Time Employees:  0 0

IPO Date:  2021-01-17 2021-01-17

CIK: 

ISIN:  AU0000121576 AU0000121576

CUSIP: 

Beta:  1.59 1.59

Last Dividend:  0.00 0.00

Dcf Diff:  0.01 0.01

Dcf:  0.00 0.00

Description

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.

Address

62 Lygon Street,
Carlton, VIC 3053, AU

61 3 9824 5254

http://www.chimerictherapeutics.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment